The guideline, written by Joseph D. Feuerstein et al, discusses the use of immunomodulators, biologics, and small molecules to induce and maintain remission in patients with moderate to severe UC and reduce the risk of colectomy.
Untreated UC is characterized by relapsing and remitting mucosal inflammation. In population-based cohort studies, most patients with UC have a mild to moderate disease course. However, approximately 15% patients have aggressive disease, and 20% of these patients require hospitalization.
The first 7 recommendations address medical management of adult outpatients with moderate to severe UC. The next 4
recommendations provide strategies for adult patients hospitalized with acute to severe UC (initial management and rescue therapy for patients with corticosteroid-refractory disease).
The authors acknowledge challenges in defining moderate disease activity and severity, with variable definition in clinical practice. The authors also recommended reading the AGA guideline on the management of mild to moderate UC.
The review the guideline will be published in Gastroenterology.